Heron Neutron Medical Corp. (TPE:7799)
Taiwan · Delayed Price · Currency is TWD 357.00
-4.50 (-1.24%)
At close: Aug 6, 2026
Heron Neutron Medical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| 11.69 | 10.31 | - | 0.24 | - | |
Revenue Growth | 482.12% | - | - | - | - |
Cost of Revenue | 29.69 | 36.09 | 3.59 | 0.11 | - |
Gross Profit | -18 | -25.78 | -3.59 | 0.13 | - |
Selling, General & Admin | 216.7 | 186.68 | 82.02 | 44.79 | 36.23 |
Research & Development | 358.01 | 321.87 | 173.39 | 84.85 | 51.57 |
Operating Expenses | 574.71 | 508.54 | 255.41 | 129.64 | 87.8 |
Operating Income | -592.71 | -534.32 | -259 | -129.51 | -87.8 |
Interest Expense | -2.36 | -0.14 | -0.18 | -0.24 | -0.28 |
Interest & Investment Income | 111.66 | 46.19 | 5.72 | 2.12 | 0.1 |
Currency Exchange Gain (Loss) | 4.38 | 6.93 | 0.43 | -0.19 | 0.48 |
Other Non Operating Income (Expenses) | -0.35 | -0.32 | - | 0.94 | - |
EBT Excluding Unusual Items | -479.38 | -481.67 | -253.03 | -126.88 | -87.49 |
Gain (Loss) on Sale of Investments | - | - | - | 0.49 | 1.31 |
Gain (Loss) on Sale of Assets | - | - | -7.05 | - | - |
Pretax Income | -479.38 | -481.67 | -260.08 | -126.39 | -86.18 |
Net Income | -479.38 | -481.67 | -260.08 | -126.39 | -86.18 |
Net Income to Common | -479.38 | -481.67 | -260.08 | -126.39 | -86.18 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 155 | 146 | 128 | 107 | 76 |
Shares Outstanding (Diluted) | 155 | 146 | 128 | 107 | 76 |
Shares Change | 11.52% | 14.17% | 19.11% | 40.45% | - |
EPS (Basic) | -3.10 | -3.31 | -2.04 | -1.18 | -1.13 |
EPS (Diluted) | -3.11 | -3.31 | -2.04 | -1.18 | -1.13 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Free Cash Flow | -718.16 | -512.21 | -302.19 | -110.76 | -173.14 |
Free Cash Flow Per Share | -4.64 | -3.52 | -2.37 | -1.03 | -2.27 |
Gross Margin | -153.96% | -250.12% | - | 54.20% | - |
Operating Margin | -5070.66% | -5183.58% | - | -54415.97% | - |
Profit Margin | -4101.11% | -4672.74% | - | -53105.04% | - |
Free Cash Flow Margin | -6143.87% | -4969.02% | - | -46536.13% | - |
EBITDA | -565.6 | -509.54 | -242.89 | -119.36 | -78.91 |
D&A For EBITDA | 27.11 | 24.79 | 16.11 | 10.15 | 8.89 |
EBIT | -592.71 | -534.32 | -259 | -129.51 | -87.8 |